IFNG and inflammatory bowel disease: Despite IL-12 inhibition, no significant effect of ustekinumab was seen on the TH1 cells (IFNγ-secreting cells), consistent with the findings in patients with inflammatory bowel disease treated with ustekinumab51,52.